Navigation Links
Cutting-Edge Vaccine Research to be Showcased at AAPS National Biotechnology Conference
Date:5/14/2010

Potential therapies for deadly diseases to be presented during San Francisco meeting

ARLINGTON, Va., May 14 /PRNewswire-USNewswire/ -- Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

Researchers from the University of Texas at Austin have developed a delivery system utilizing invasin as a targeting molecule to M cells as well as an agent that can enhance the patient's immune response. This formulation may be useful in developing countries due to its stable powder form, which reduces the need for trained personnel to administer the medication. This platform oral vaccine system being developed by Tarik Khan and Jennifer Maynard, Ph.D. in collaboration with Margaret Phillips and Nicholas Peppas, Sc.D., targets immune cells in the gut, and may be applied to a number of diseases including flu, whooping cough, and HIV.

"By vaccinating through the oral route you remove the pain and fear associated with vaccines, require less experienced personnel for administration, and do a better job of mimicking the natural process of infection," said Khan.

It is hoped that a vaccination system, such as the one developed by Khan and Maynard, will increase patient compliance, the overall vaccination rate, and allow for widespread distribution in the developing world where diseases such as the flu and HIV are particularly deadly. This study is currently being evaluated with a model antigen in the mouse model.

Powder-based vaccinations are also the focus of research being conducted by researchers from the Aeras Global TB Vaccine Foundation and Crucell pharmaceuticals. The study, "Stabilizing Formulations for Inhalable Powders of an Adenovirus 35-vectored Tuberculosis (TB) Vaccine," demonstrates that it is possible to produce a stable dry powder formulation of a TB vaccine suitable for mass vaccination in a one-step drying process. The powder formulation helps stabilize the vaccine so variations in temperature will not negatively affect its effectiveness or shelf life.

Recent clinical trials showed that the liquid Adenovirus 35-vectored TB vaccine was safe in healthy adults. A booster shot of this vaccine stimulated the immune system in a manner thought to be important for protection against TB, which included activation of CD4 and CD8 T-cells. Animal studies for the powder-based vaccine are being planned.

These studies and other novel research will be presented during a week of educational programming devoted to advancing health through biotherapeutics. Conference programming consists of a Plenary Session, symposia, roundtables, posters, hot topics, and concludes with two short courses. Additionally, the Exposition Hall will be hosting over 100 companies.

For more information visit, http://www.aapspharmaceutica.com/meetings/workshops/NBC/index.asp.

About AAPS

The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 12,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to serve the public and enhance their contributions to health. AAPS offers timely scientific programs, on-going education, information resources, opportunities for networking, and professional development. 

Editor's Note

Registration is complimentary for members of the media. All abstracts presented at NBC are available upon request. To register for the meeting or to set up an interview with a pharmaceutical expert, please contact Joseph Catapano at (703) 248-4772 or CatapanoJ@aaps.org prior to May 16. For the period of May 16-May 20, contact Stacey May on site at (703) 459-7677 or MayS@aaps.org.


'/>"/>
SOURCE American Association of Pharmaceutical Scientists
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Commends Honeywell Enraf for Cutting-Edge Products and Post-Sales Support
2. Scotland Highlights New Partnerships and Cutting-Edge Drug Discovery Research
3. Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research
4. eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
8. Anthrax vaccine produces immunity with nanoparticles, not needles
9. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... Cambrian ... for industrial facilities, today announced that one of the nation’s fastest growing craft ... novel water-energy purchase agreement (WEPA). Under the WEPA, a first for the industrial ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO ... online shopping cart. The new website has been designed to provide the best ... allow customers to access detailed product information, read educational industry content as well ...
(Date:12/7/2016)... ... 07, 2016 , ... Kara Dwyer Dodge grew up hearing stories of the sea monster her ... Mass., found a sea turtle entangled in the lines of one of his lobster pots. ... sensation because no one could remember ever seeing one so large so close to shore. ...
(Date:12/6/2016)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: ... and fiscal year ended September 30, 2016. ... , , ... diagnostics company that develops and commercializes proprietary technologies and products for ... Achieved revenues of $1.4 million more than tripling prior years revenue. ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... DUBLIN , Nov 15, 2016 Research ... - Global Forecast to 2021" report to their offering. ... ... reach USD 16.18 Billion by 2021 from USD 6.21 Billion in ... Growth of the bioinformatics market is driven by ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
Breaking Biology News(10 mins):